Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia

British Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2008, Pages 826-837

  Hawwa, Ahmed F ^a   Collier, Paul S ^a   Millership, Jeff S ^a   McCarthy, Anthony ^b   Dempsey, Sid ^b   Cairns, Carole ^b   McElnay, James C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

6 mercaptopurine; Acute lymphoblastic leukaemia; NONMEM; Pharmacogenetics; Population pharmacokinetics

Indexed keywords

DRUG METABOLITE; INOSINE TRIPHOSPHATASE; MERCAPTOPURINE; METHOTREXATE; PHOSPHATASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; VINCRISTINE; XANTHINE OXIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PHARMACOGENETICS; PHARMACOKINETICS; POPULATION PHARMACOKINETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TITRIMETRY;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHYLTRANSFERASES; MODELS, BIOLOGICAL; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES;

EID: 56549088409     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03281.x     Document Type: Article

References (25)

1. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986 40 : 287 92.
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992 43 : 329 39.
3. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006 24 : 715 29.
4. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986 35 : 3533 41.
5. Elion GB. The purine path to chemotherapy. Science 1989 244 : 41 7.
6. Cara CJ, Pena AS, Sans M, Rodrigo L, Guerrero-Esteo M, Hinojosa J, Garcia-Paredes J, Guijarro LG. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004 10 : RA247 54.
7. Hawwa AF, Millership JS, Collier PS, McElnay JC. Improved HPLC methodology for the determination of mercaptopurine and its metabolites in plasma and red blood cells. J Pharm Pharmacol 2006 58 (Suppl. 1 A3.
8. Beal SL, Sheiner LB, Boeckmann AJ (eds). NONMEMU Users Guides. Ellicott City, MD : Icon Development Solutions, 1989-2006.
9. Chabner B, Amrein P, Druker B. Chemotherapy of neoplastic diseases. In : Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th edn, eds Brunton L, Lazo J, Parker K. New York, NY : McGraw-Hill, 2006 1315 1405.
10. Food and Drug Administration Guidance for Industry. Guidance for Industry: Population Pharmacokinetics. Rockville, MD : U.S. Department of Health and Human Services, 1999.
11. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 9 : 503 12.
12. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 32.
13. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989 7 : 1816 23.
14. Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci 1999 8 : 329 34.
15. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989 16 : 327 36.
16. McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992 18 : S23 9.
17. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958 18 : 853 6.
18. Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) 2007 19 : 23 37.
19. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989 5 : 303, 11 discussion 312-3.
20. Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993 32 : 411 8.
21. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983 308 : 1005 9.
22. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991 119 : 985 9.
23. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006 25 : 1629 38.
24. Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst 1999 91 : 1983 5.
25. Mawatari H, Unei K, Nishimura S, Sakura N, Ueda K. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. Pediatr Int 2001 43 : 673 7.